Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 8/20 | 0.48 |
| ▸ | CTSS | P25774 | 5/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7364210 | 1.00 | MEN1 (0.55) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL1486276 | 1.00 | MEN1 (0.55) | MEN1GAAKMT2ACTSKCTSS | |
| Hydrochloric Acid SCHEMBL7264801 | 0.99 | MEN1 (0.54) | MEN1GAAKMT2ACTSKCTSS | |
| Hydrochloric Acid SCHEMBL8630295 | 0.99 | MEN1 (0.54) | MEN1GAAKMT2ACTSKCTSS | |
| Hydrochloric Acid SCHEMBL10444447 | 0.99 | MEN1 (0.54) | MEN1GAAKMT2ACTSKCTSS | |
| Water SCHEMBL10332189 | 0.99 | MEN1 (0.54) | MEN1GAAKMT2ACTSKCTSS | |
| Water SCHEMBL10332190 | 0.99 | MEN1 (0.54) | MEN1GAAKMT2ACTSKCTSS | |
| Hydrochloric Acid SCHEMBL10932432 | 0.97 | MEN1 (0.52) | MEN1GAAKMT2ACTSKCTSS | |
| Hydrochloric Acid SCHEMBL10723070 | 0.97 | MEN1 (0.52) | MEN1GAAKMT2ACTSKCTSS | |
| Hydrochloric Acid SCHEMBL7304854 | 0.97 | MEN1 (0.52) | MEN1GAAKMT2ACTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119899242-A | Method for producing AMG416 | 美国安进公司 | 2025-04-29 | — | — | CN | claimed |
| CN-119874825-A | Method for producing AMG416 | 美国安进公司 | 2025-04-25 | — | — | CN | claimed |
| US-20250002531-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-01-02 | — | — | US | claimed |
| EP-4219526-A2 | METHOD FOR PREPARING AMG 416 | AMGEN, INC. (US) | 2023-08-02 | — | — | EP | claimed |
| EP-3708576-B1 | METHOD FOR PREPARING AMG 416 | AMGEN INC (US) | 2023-02-22 | — | — | EP | claimed |
| CN-111944016-B | Preparation method of icatibant acetate | 台州吉诺生物科技有限公司 | 2022-04-29 | — | — | CN | claimed |
| EP-4725506-A2 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-3986401-B1 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | STEALTH BIOTHERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12404300-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-09-02 | — | — | US | disclosed |
| CN-119899242-A | Method for producing AMG416 | 美国安进公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119874825-A | Method for producing AMG416 | 美国安进公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20240398966-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-12-05 | — | — | US | disclosed |
| CN-113544138-B | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-102037092-A | Amino acid generator and polysiloxane composition containing the same | NISSAN CHEMICAL IND LTD | 2011-04-27 | — | — | CN | disclosed |
| EP-2004670-B1 | PROCESS FOR THE MANUFACTURE OF LYSOBACTIN DERIVATIVES | AICURIS GMBH & CO KG (DE) | 2010-01-27 | — | — | EP | disclosed |
| US-20090163696-A1 | METHOD FOR PREPARING LYSOBACTIN DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2009-06-25 | — | — | US | disclosed |
| CN-101466729-A | Lysobactin amides | AICURIS GMBH & CO KG (DE) | 2009-06-24 | — | — | CN | disclosed |
| CN-101421291-A | Process for the manufacture of lysobactin derivatives | AICURIS GMBH & CO KG (DE) | 2009-04-29 | — | — | CN | disclosed |
| EP-2007794-A1 | LYSOBACTIN AMIDES | AiCuris GmbH & Co. KG (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007118691-A1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002531-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | ADM2, VIP, PEPD | MEN1 194/4885GAA 1903/4885KMT2A 767/4885 |
| US-20090163696-A1 | METHOD FOR PREPARING LYSOBACTIN DERIVATIVES | DLST, VIP, HAMP | MEN1 1192/4885GAA 683/4885KMT2A 1908/4885 |
| US-12404300-B2 | Mitochondria-targeting peptides | SSBP1, HSPE1, IMMT | MEN1 4778/4885GAA 2004/4885KMT2A 4583/4885 |
| US-20240398966-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | MEN1 2346/4885GAA 197/4885KMT2A 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.